PMID- 24576655
OWN - NLM
STAT- MEDLINE
DCOM- 20140421
LR  - 20181202
IS  - 1532-8708 (Electronic)
IS  - 0093-7754 (Linking)
VI  - 41 Suppl 2
DP  - 2014 Feb
TI  - Management of common adverse events in patients treated with sorafenib: nurse and 
      pharmacist perspective.
PG  - S17-28
LID - S0093-7754(14)00003-7 [pii]
LID - 10.1053/j.seminoncol.2014.01.002 [doi]
AB  - Sorafenib, a tyrosine kinase inhibitor, is indicated for the treatment of 
      patients with unresectable hepatocellular carcinoma (HCC) and advanced renal cell 
      carcinoma (RCC). Sorafenib is currently being evaluated in phase II and III 
      trials in various malignancies as a single agent (locally advanced/metastatic 
      radioactive iodine-refractory differentiated thyroid cancer [DTC]), as part of 
      multimodality care (HCC), and in combination with chemotherapies (metastatic 
      breast cancer). Grade 1 and 2 adverse events (AEs) that commonly occur during 
      treatment (ie, dermatologic manifestations, diarrhea, fatigue, and hypertension) 
      should be proactively managed. The goal is to allow patients to remain on their 
      full dose of sorafenib for as long as their treatment is indicated. A combination 
      of early recognition of and intervention for AEs, patient education, and an open 
      dialogue between patients and their multidisciplinary healthcare team, with 
      timely reporting of AEs, will allow for effective management of AEs and minimize 
      the need for sorafenib dose reduction or discontinuation.
CI  - Copyright (c) 2014 Elsevier Inc. All rights reserved.
FAU - Walko, Christine M
AU  - Walko CM
AD  - Applied Clinical Scientist, Moffitt Cancer Center, Tampa, FL.
FAU - Grande, Carolyn
AU  - Grande C
AD  - Nurse Practitioner, Hospital of the University of Pennsylvania, Department of 
      Otorhinolaryngology, Philadelphia, PA. Electronic address: 
      Carolyn.Grande@uphs.upenn.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140109
PL  - United States
TA  - Semin Oncol
JT  - Seminars in oncology
JID - 0420432
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phenylurea Compounds)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Antineoplastic Agents/*adverse effects/therapeutic use
MH  - Carcinoma, Hepatocellular/drug therapy
MH  - Carcinoma, Renal Cell/drug therapy
MH  - Disease Management
MH  - Fatigue/chemically induced/therapy
MH  - Gastrointestinal Diseases/chemically induced/therapy
MH  - Hand-Foot Syndrome/*etiology/therapy
MH  - Humans
MH  - Hypertension/*chemically induced/therapy
MH  - Kidney Neoplasms/drug therapy
MH  - Liver Neoplasms/drug therapy
MH  - Niacinamide/adverse effects/*analogs & derivatives/therapeutic use
MH  - Nurses
MH  - Patient Education as Topic
MH  - Pharmacists
MH  - Phenylurea Compounds/*adverse effects/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Sorafenib
EDAT- 2014/03/01 06:00
MHDA- 2014/04/22 06:00
CRDT- 2014/03/01 06:00
PHST- 2014/03/01 06:00 [entrez]
PHST- 2014/03/01 06:00 [pubmed]
PHST- 2014/04/22 06:00 [medline]
AID - S0093-7754(14)00003-7 [pii]
AID - 10.1053/j.seminoncol.2014.01.002 [doi]
PST - ppublish
SO  - Semin Oncol. 2014 Feb;41 Suppl 2:S17-28. doi: 10.1053/j.seminoncol.2014.01.002. 
      Epub 2014 Jan 9.